Estadístiques de Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Visites totals

views
Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) 274

Visites totals per mes

views
September 2024 4
October 2024 0
November 2024 0
December 2024 0
January 2025 0
February 2025 0
March 2025 0

Visites al fitxer

views
mereu_anno_dual.pdf(legacy) 239
mereu_anno_dual.pdf 39

Vistes principals per país

views
United States 188
Spain 25
Ireland 15
Germany 12
China 5
Sweden 5
France 4
United Kingdom 4
Japan 3
Canada 2
Mexico 2
Slovenia 2
Argentina 1
Australia 1
Czechia 1
India 1
Netherlands 1
Turkey 1
Ukraine 1

Visites principals per ciutat

views
Ashburn 50
Fairfield 39
Barcelona 21
San Ramon 17
Dublin 15
Cambridge 10
Ann Arbor 9
Boardman 8
Mountain View 8
Menlo Park 7
Seattle 4
Shenzhen 4
Jacksonville 2
Mexico 2
Redwood City 2
San Diego 2
Toronto 2
Carcastillo 1
Jerez 1
Magdeburg 1
Mumbai 1
Philadelphia 1
Rochester 1
Ríudoms 1
Shenyang 1
Suipacha 1
Telde 1
Uppsala 1